Nuvectis Pharma (NVCT) Interest & Investment Income (2022 - 2026)
Nuvectis Pharma's (NVCT) quarterly Interest & Investment Income came in at $210000.0 in Q1 2026, down 11.02% year-on-year from $236000.0 in Q1 2025, and down 30.69% quarter-over-quarter from $303000.0 in Q4 2025.
Nuvectis Pharma (NVCT) Interest & Investment Income (2022 - 2026) Analysis & Trends
Nuvectis Pharma has disclosed Interest & Investment Income across 5 years of filings, most recently posting $210000.0 for Q1 2026.
- Interest & Investment Income for Q1 2026 came in at $210000.0, down 11.02% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (up 28.9% YoY), and the FY2025 annual result was $1.1 million, up 33.65% from the prior year.
- Interest & Investment Income came in at $210000.0 for Q1 2026 at Nuvectis Pharma, down from $303000.0 in the prior quarter.
- In the past five years, Interest & Investment Income ranged from a high of $332000.0 in Q3 2025 to a low of $2000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $210000.0 (2026), against an average of $175000.0.
- Across the five-year window, Interest & Investment Income jumped 2500.0% in 2023 and dropped 25.63% in 2024, its largest moves.
- Nuvectis Pharma's Interest & Investment Income stood at $82000.0 in 2022, then soared by 197.56% to $244000.0 in 2023, then decreased by 17.62% to $201000.0 in 2024, then surged by 50.75% to $303000.0 in 2025, then plunged by 30.69% to $210000.0 in 2026.
- The last three Interest & Investment Income figures came in at $210000.0 (Q1 2026), $303000.0 (Q4 2025), and $332000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 597,319.59 |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 40.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 103,341.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 114.80 Mn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -14.79 Mn |
| 10 | Nuvectis Pharma | 274.90 Mn | 274.90 Mn | - | 210,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 210,000.00 |
| Dec 31, 2025 | 303,000.00 |
| Sep 30, 2025 | 332,000.00 |
| Jun 30, 2025 | 261,000.00 |
| Mar 31, 2025 | 236,000.00 |
| Dec 31, 2024 | 201,000.00 |
| Sep 30, 2024 | 206,000.00 |
| Jun 30, 2024 | 215,000.00 |
| Mar 31, 2024 | 225,000.00 |
| Dec 31, 2023 | 244,000.00 |
| Sep 30, 2023 | 277,000.00 |
| Jun 30, 2023 | 64,000.00 |
| Mar 31, 2023 | 52,000.00 |
| Dec 31, 2022 | 82,000.00 |
| Sep 30, 2022 | 61,000.00 |
| Jun 30, 2022 | 4,000.00 |
| Mar 31, 2022 | 2,000.00 |